Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-MIRC213 SPECT/CT in Breast Cancer
NCT05622240Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Nanobodies (VHH), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 99mTc-MIRC213 in breast cancer (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dosimetric distribution of radiopharmaceuticals at 2 months and Standardized uptake value at 1 year. Status: unknown.
02
Drugs
99mTc-MIRC213
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05622240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622240.